Resproly Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 74

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $7.12M

  • Investors
  • 14

Resproly General Information

Description

Developer and provider of inhaled formulations and pulmonary drug delivery technology for respiratory disease. The company is mainly focuses on the research and development of treatments for Asthma, COPD (Chronic Obstructive Pulmonary Disease), diabetes, and Parkinson's Disease.

Contact Information

Formerly Known As
Zhuhai Resproly Bio Pharmaceutical Co., Ltd
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 683, Block A, Huameiju Business Center, Xinhu Road, District 82, Haiyu Community
  • Xin'an Street, Bao'an District
  • Shenzhen, Guangdong 518102
  • China
+86 0755
Primary Industry
Drug Delivery
Corporate Office
  • Room 683, Block A, Huameiju Business Center, Xinhu Road, District 82, Haiyu Community
  • Xin'an Street, Bao'an District
  • Shenzhen, Guangdong 518102
  • China
+86 0755

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Resproly Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 15-Apr-2026 $7.12M Completed Generating Revenue
8. IPO 27-Jun-2025 Completed Clinical Trials - General
7. Later Stage VC 30-Apr-2022 Completed Clinical Trials - General
6. Secondary Transaction - Private 22-Apr-2022 Completed Clinical Trials - General
5. Secondary Transaction - Private 02-Apr-2021 Completed Clinical Trials - General
4. Early Stage VC (Series B) 01-Feb-2021 Completed Clinical Trials - General
3. Early Stage VC 28-Feb-2020 Completed Clinical Trials - General
2. Early Stage VC (Series A) 25-Sep-2019 $7.02M $11.8M Completed Clinical Trials - General
1. Seed Round 01-May-2018 $4.76M $4.76M Completed Startup
To view Resproly’s complete valuation and funding history, request access »

Resproly Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 6,923,077 $1.12 $1.12 1x $1.12 17.41%
To view Resproly’s complete cap table history, request access »

Resproly Patents

Resproly Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026138739-A1 Il-4r binding molecule and use thereof Pending 26-Dec-2024
US-11475798-B2 Simulation device for characterizing aerodynamics of dry power inhalants in respiratory system Active 11-Jun-2019
US-20200394937-A1 Simulation device for characterizing aerodynamics of dry power inhalants in respiratory system Active 11-Jun-2019
GB-201905668-D0 A device for measuring tablet and granule dissolution and disintegration Inactive 23-Apr-2019
GB-2583468-A A device for measuring tablet and granule dissolution and disintegration Inactive 23-Apr-2019 G01N13/00
To view Resproly’s complete patent history, request access »

Resproly Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Resproly Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Guangzhou Industrial Investment Holding Group Government Minority
Fuho Capital Venture Capital Minority
CAS Investment Management Growth/Expansion Minority
Cowin Capital Venture Capital Minority
Qianhai FoF Fund of Funds Minority
You’re viewing 5 of 14 investors. Get the full list »

Resproly FAQs

  • When was Resproly founded?

    Resproly was founded in 2018.

  • Where is Resproly headquartered?

    Resproly is headquartered in Shenzhen, China.

  • What is the size of Resproly?

    Resproly has 74 total employees.

  • What industry is Resproly in?

    Resproly’s primary industry is Drug Delivery.

  • Is Resproly a private or public company?

    Resproly is a Private company.

  • What is the current valuation of Resproly?

    The current valuation of Resproly is .

  • What is Resproly’s current revenue?

    The current revenue for Resproly is .

  • How much funding has Resproly raised over time?

    Resproly has raised $61.8M.

  • Who are Resproly’s investors?

    Guangzhou Industrial Investment Holding Group, Fuho Capital, CAS Investment Management, Cowin Capital, and Qianhai FoF are 5 of 14 investors who have invested in Resproly.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process